



## Agenus to Present at the 2018 Jefferies London Healthcare Conference

November 13, 2018

LEXINGTON, Mass., Nov. 13, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies<sup>1</sup>, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the 2018 Jefferies London Healthcare Conference in London, UK.



### Details of the presentation and live webcast are provided below:

- Presentation Date and Time: November 14, at 12:40pm – 1:15pm (GMT); 7:40am – 8:15am (EST)
- A live audio webcast will be accessible at: <http://wsw.com/webcast/jeff115/agen/>
- Webcast will be also accessible from the "[Events & Presentations](#)" section of the Company's investor website at [www.agenusbio.com](http://www.agenusbio.com). A replay will be available following the presentation.

### **About Agenus**

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit [www.agenusbio.com](http://www.agenusbio.com) and our twitter handle [@agenus bio](#). Information that may be important to investors will be routinely posted on our website and twitter.

### **Forward-Looking Statements**

*This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' upcoming presentation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.*

### **Contact:**

Agenus Inc.  
Jennifer Buell, PhD  
781-674-4420  
[Jennifer.Buell@agenusbio.com](mailto:Jennifer.Buell@agenusbio.com)

<sup>1</sup>Through AgenTus Therapeutics, a subsidiary of Agenus

SOURCE Agenus Inc.